Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

150 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Structure-based discovery of thiosemicarbazones as SARS-CoV-2 main protease inhibitors.
Maltarollo VG, da Silva EB, Kronenberger T, Sena Andrade MM, de Lima Marques GV, Cândido Oliveira NJ, Santos LH, Oliveira Rezende Júnior C, Cassiano Martinho AC, Skinner D, Fajtová P, M Fernandes TH, Silveira Dos Santos ED, Rodrigues Gazolla PA, Martins de Souza AP, da Silva ML, Dos Santos FS, Lavorato SN, Oliveira Bretas AC, Carvalho DT, Franco LL, Luedtke S, Giardini MA, Poso A, Dias LC, Podust LM, Alves RJ, McKerrow J, Andrade SF, Teixeira RR, Siqueira-Neto JL, O'Donoghue A, de Oliveira RB, Ferreira RS. Maltarollo VG, et al. Among authors: dias lc. Future Med Chem. 2023 Jun;15(11):959-985. doi: 10.4155/fmc-2023-0034. Epub 2023 Jul 12. Future Med Chem. 2023. PMID: 37435731
Benzimidazole inhibitors of the major cysteine protease of Trypanosoma brucei.
Pereira GA, Santos LH, Wang SC, Martins LC, Villela FS, Liao W, Dessoy MA, Dias LC, Andricopulo AD, Costa MA, Nagem RA, Caffrey CR, Liedl KR, Caffarena ER, Ferreira RS. Pereira GA, et al. Among authors: dias lc. Future Med Chem. 2019 Jul;11(13):1537-1551. doi: 10.4155/fmc-2018-0523. Future Med Chem. 2019. PMID: 31469332 Free PMC article.
Discovery of Potent, Reversible, and Competitive Cruzain Inhibitors with Trypanocidal Activity: A Structure-Based Drug Design Approach.
de Souza ML, de Oliveira Rezende Junior C, Ferreira RS, Espinoza Chávez RM, Ferreira LLG, Slafer BW, Magalhães LG, Krogh R, Oliva G, Cruz FC, Dias LC, Andricopulo AD. de Souza ML, et al. Among authors: dias lc. J Chem Inf Model. 2020 Feb 24;60(2):1028-1041. doi: 10.1021/acs.jcim.9b00802. Epub 2019 Dec 11. J Chem Inf Model. 2020. PMID: 31765144
Structure-Based and Molecular Modeling Studies for the Discovery of Cyclic Imides as Reversible Cruzain Inhibitors With Potent Anti-Trypanosoma cruzi Activity.
Ferreira RAA, Pauli I, Sampaio TS, de Souza ML, Ferreira LLG, Magalhães LG, Rezende CO Jr, Ferreira RS, Krogh R, Dias LC, Andricopulo AD. Ferreira RAA, et al. Among authors: dias lc. Front Chem. 2019 Nov 25;7:798. doi: 10.3389/fchem.2019.00798. eCollection 2019. Front Chem. 2019. PMID: 31824926 Free PMC article.
Multiparameter Optimization of Trypanocidal Cruzain Inhibitors With In Vivo Activity and Favorable Pharmacokinetics.
Pauli I, Rezende CO Jr, Slafer BW, Dessoy MA, de Souza ML, Ferreira LLG, Adjanohun ALM, Ferreira RS, Magalhães LG, Krogh R, Michelan-Duarte S, Del Pintor RV, da Silva FBR, Cruz FC, Dias LC, Andricopulo AD. Pauli I, et al. Among authors: dias lc. Front Pharmacol. 2022 Jan 5;12:774069. doi: 10.3389/fphar.2021.774069. eCollection 2021. Front Pharmacol. 2022. PMID: 35069198 Free PMC article.
Structure-activity relationships of novel N-imidazoylpiperazines with potent anti-Trypanosoma cruzi activity.
Espinoza-Chávez RM, Oliveira Rezende Júnior C, de Souza ML, Pauli I, Valli M, Gomes Ferreira LL, Chelucci RC, Michelan-Duarte S, Krogh R, Romualdo da Silva FB, Cruz FC, de Oliveira AS, Andricopulo AD, Dias LC. Espinoza-Chávez RM, et al. Among authors: dias lc. Future Med Chem. 2024 Feb;16(3):253-269. doi: 10.4155/fmc-2023-0185. Epub 2024 Jan 9. Future Med Chem. 2024. PMID: 38193294
150 results